Alector launches novel antidiabetic Forxiga
Date: 01 Sep 2014

Alector Pharmaceuticals is launching the novel AstraZeneca oral antidiabetic Forxiga (dapagliflozin) for the treatment of type 2 diabetes mellitus. Dapagliflozin is a selective and reversible inhibitor of sodium-glucose cotransporter 2 (SGLT2), which works independently of insulin.

For more information about Forxiga click here.